Corient Private Wealth
SYRS

Corient Private Wealth’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Corient Private Wealth’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,000
Closed -$2.76K – 2478
2024
Q4 		$2.76K Hold
12,000
– – ﹤0.01% 2335
2024
Q3 		$25.8K Hold
12,000
– – ﹤0.01% 2424
2024
Q2 		$61.9K Hold
12,000
– – ﹤0.01% 2245
2024
Q1 		$64.2K Hold
12,000
– – ﹤0.01% 2217
2023
Q4 		$93.5K Sell
12,000
-14,666
-55% -$50.2K ﹤0.01% 2162
2023
Q3 		$105K Hold
26,666
– – ﹤0.01% 2017
2023
Q2 		$84K Hold
26,666
– – ﹤0.01% 1989
2023
Q1 		$71.2K Buy
+26,666
New +$103K ﹤0.01% 1917

Other funds holding SYRS

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Corient Private Wealth's SYRS Position: Q1 2025 in Review

Corient Private Wealth sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2025, closing a stake of 12,000 shares — an estimated $2.76K sold.

Corient Private Wealth first reported a position in SYRS in Q1 2023 and held it in 8 quarters. The position peaked at $105K in Q3 2023. 7 funds tracked by Wall St. Rank hold SYRS as of Q1 2025.

  • Corient Private Wealth reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Corient Private Wealth sold 12,000 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $2.76K.
  • Corient Private Wealth first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q1 2023 and held it in 8 quarters.
  • Corient Private Wealth's Syros Pharmaceuticals, Inc. Common Stock position peaked at $105K in Q3 2023.
  • 7 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2025.

Based on Corient Private Wealth's 13F filing for Q1 2025, filed 14 May 2025.